Expert Interview
Discussing Anteris’ DurAVR® Transcatheter Heart Valve (THV) for the treatment of aortic stenosis ahead of pivotal Phase 3 PARADIGM trial
Ticker(s): AVR, EW, MDT, ABTInstitution: University of Vermont Health
- Interventional cardiologist at the University of Vermont Medical Center.
- Treats 325 patients with aortic stenosis and performs 10+ Renal Denervation Procedures annually
- Actively involved in clinical trials and database research focused on interventional cardiology and heart valve therapies.
Roughly how many patients with severe aortic stenosis do you evaluate or treat for TAVR each year?
Added By: sara_adminHow do current commercial TAVR devices perform in small annuli patients in your practice, and what unmet needs remain that a valve like DurAVR® may address?
Added By: sara_adminWhat are your impressions of the PARADIGM pivotal trial design, and what data would you need to see to adopt a new biomimetic TAVR platform into routine practice?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
